Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 14/20 | 0.57 |
| ▸ | EPAS1 | Q99814 | 14/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Achyrofuran SCHEMBL29375603 | 1.00 | HIF1A (0.57) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL24075656 | 0.75 | HIF1A (0.56) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL29517025 | 0.74 | HIF1A (0.70) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL30377279 | 0.72 | HIF1A (0.78) | HIF1AEPAS1 | |
| SCHEMBL29934508 | 0.71 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL6907224 | 0.69 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL31237267 | 0.69 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL6914633 | 0.68 | HIF1A (1.00) | HIF1AEPAS1 | |
| Rhodomyrtoxin B SCHEMBL12827333 | 0.68 | MAPT (1.00) | HIF1AEPAS1MEN1LMNATP53 | |
| SCHEMBL24074938 | 0.67 | PTGES (0.57) | HIF1AEPAS1PTGESALOX5PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522139-B2 | Fructose 1, 6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-12-20 | — | — | US | claimed |
| US-20130143910-A1 | Fructose-1,6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis | UNIVERSITY OF HOUSTON SYSTEM | 2013-06-06 | — | — | US | claimed |
| WO-2013074581-A1 | FRUCTOSE-1,6-BIPHOSPHATASES AS NEW TARGETS FOR DIAGNOSING AND TREATING BREAST CANCER BRAIN METASTASIS | WEIHUA ZHANG (US) | 2013-05-23 | — | — | WO | claimed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | claimed |
| WO-2010091185-A2 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2010-08-12 | — | — | WO | claimed |
| US-9522139-B2 | Fructose 1, 6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-12-20 | — | — | US | disclosed |
| US-9273021-B2 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273021-B2 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273021-B2 | Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2512495-B1 | PROCESS FOR OBTAINING A STANDARDISED EXTRACT OF QUERCETIN AN 3-O-METHYLQUERCETIN FROM FLOWERS OF MACELA (ACHYROCLINE SATUREIOIDES), AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID EXTRACT | NATURA COSMETICOS SA (BR) | 2015-09-09 | — | — | EP | disclosed |
| US-20130143910-A1 | Fructose-1,6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis | UNIVERSITY OF HOUSTON SYSTEM | 2013-06-06 | — | — | US | disclosed |
| WO-2013074581-A1 | FRUCTOSE-1,6-BIPHOSPHATASES AS NEW TARGETS FOR DIAGNOSING AND TREATING BREAST CANCER BRAIN METASTASIS | WEIHUA ZHANG (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-2512495-A1 | PROCESS FOR OBTAINING A STANDARDISED EXTRACT OF QUERCETIN AND 3-0-METHYLQUERCETIN FROM FLOWERS OF MACELA (ACHYROCLINE SATUREIOIDES), AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID EXTRACT | Natura Cosméticos S.A. (BR) | 2012-10-24 | — | — | EP | disclosed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011073961-A1 | PROCESS FOR OBTAINING A STANDARDISED EXTRACT OF QUERCETIN AND 3-0-METHYLQUERCETIN FROM FLOWERS OF MACELA (ACHYROCLINE SATUREIOIDES), AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID EXTRACT | NATURA COSMETICOS S.A (BR) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010091185-A2 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091185-A2 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON COLLEGE (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20030055103-A1 | Utilization of achyrocline satureoides (\"Marcela\") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases | HEINZEN HORACIO (UY) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055103-A1 | Utilization of achyrocline satureoides (\"Marcela\") extracts and liposomal preparations of natural and semi-synthetic flavonoids for the prevention and treatment of the consequences of stroke and neurodegenerative diseases | ACHE, KYNU, NLN | HIF1A 3408/4885EPAS1 4415/4885MEN1 3804/4885 |
| US-20120028892-A1 | INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE AND METHODS OF USE THEREOF | FBP1, SLC5A1, ALDOA | HIF1A 851/4885EPAS1 1902/4885MEN1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.